GBIO

Generation Bio Co. is a biotechnology company developing genetic medicines for rare and prevalent diseases using its proprietary non-viral gene therapy platform. The company's closed-ended DNA (ceDNA) technology is designed to enable durable and redosable gene therapy, addressing key limitations of viral vector-based approaches. Generation Bio's platform includes a cell-targeted lipid nanoparticle delivery system that aims to selectively deliver genetic payloads to specific tissues. The company's pipeline includes programs targeting liver, retinal, and other tissues for both monogenic diseases and more common conditions. Generation Bio is working to advance multiple clinical-stage programs while continuing to enhance its platform capabilities.